SCHEMBL890223

SCHEMBL890223

Cc1ccc2cc(C)c(=O)oc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 1/20 0.68
ALDH1A1 P00352 2/20 0.53
MAOB P27338 9/20 0.53
MIF P14174 1/20 0.49
HSD11B1 P28845 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA4 P22748 2/20 0.45
CA5A P35218 2/20 0.45
CA7 P43166 2/20 0.45
CA5B Q9Y2D0 2/20 0.45
CA9 Q16790 2/20 0.45
CA6 P23280 1/20 0.45
CA14 Q9ULX7 1/20 0.45
NOS1 P29475 1/20 0.43
CYP1A2 P05177 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13769008 0.84 MAOB (0.65) ALDH1A1MAOBMIFADORA3PON1
SCHEMBL31558612 0.84 MAOB (0.64) HSD17B3ALDH1A1MAOBADORA3CA12
SCHEMBL8344553 0.84 MAOB (0.64) HSD17B3ALDH1A1MAOBADORA3CA12
SCHEMBL4077523 0.81 AKR1B1 (0.59) HSD17B3ALDH1A1MAOBMIFHSD11B1
SCHEMBL8755758 0.81 POLB (0.59) HSD17B3ALDH1A1MAOBMIFHSD11B1
SCHEMBL23332349 0.81 MAOB (0.56) HSD17B3ALDH1A1MAOBMIFHSD11B1
SCHEMBL14962634 0.81 MAOB (0.57) HSD17B3ALDH1A1MAOBMIFHSD11B1
SCHEMBL31415663 0.81 HSD17B3 (0.64) HSD17B3ALDH1A1MAOBMIFCA12
SCHEMBL29384323 0.81 HSD17B3 (0.64) HSD17B3ALDH1A1MAOBMIFCA12
SCHEMBL126040 0.81 HSD17B3 (1.00) HSD17B3ALDH1A1MIFCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9127092-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2015-09-08 US claimed
US-20140187725-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORPORATION (JP) 2014-07-03 US claimed
US-20230229084-A1 CHEMICALLY AMPLIFIED PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE DRY FILM, PRODUCTION METHOD OF SUBSTRATE HAVING TEMPLATE FOR PLATING, AND PRODUCTION METHOD OF PLATED ARTICLE TOKYO OHKA KOGYO CO., LTD. (JP) 2023-07-20 US disclosed
WO-2023012459-A1 SULPHIDE SENSOR OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-02-09 WO disclosed
US-11072742-B2 Liquid-crystalline media having homeotropic alignment MERCK PATENT GMBH (DE) 2021-07-27 US disclosed
EP-3521401-B1 COMPOUNDS FOR HOMEOTROPIC ALIGNMENT OF LIQUID CRYSTALINE MEDIA MERCK PATENT GMBH (DE) 2021-04-21 EP disclosed
EP-3510122-B1 LIQUID-CRYSTAL MEDIA AND LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-12-16 EP disclosed
EP-3730590-A1 LIQUID CRYSTAL MEDIA WITH HOMEOTROPIC ALIGNMENT Merck Patent GmbH (DE) 2020-10-28 EP disclosed
EP-3502209-B1 LIQUID-CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT MERCK PATENT GMBH (DE) 2020-10-14 EP disclosed
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element DIC CORPORATION (JP) 2020-08-11 US disclosed
EP-2918658-B1 Liquid crystalline media with homeotropic alignment MERCK PATENT GMBH (DE) 2020-05-13 EP disclosed
US-20110064696-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20110008288-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-01-13 US disclosed
US-20100316607-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2010-12-16 US disclosed
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-10-21 US disclosed
US-20100260715-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2010-10-14 US disclosed
CN-101861340-A Method for producing thickener dispersions BASF SE 2010-10-13 CN disclosed
US-20070123690-A1 Conjugated polymers, representation thereof, and use of the same MERCK PATENT GMBH (DE) 2007-05-31 US disclosed
US-7169931-B2 Cell differentiation, cell proliferation SHIONOGI & CO., LTD. (JP) 2007-01-30 US disclosed
US-7169931-B2 Cell differentiation, cell proliferation SHIONOGI & CO., LTD. (JP) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100260715-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 HSD17B3 597/4885ALDH1A1 365/4885MAOB 1610/4885
US-20100316607-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 HSD17B3 597/4885ALDH1A1 365/4885MAOB 1610/4885
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element PYM1, ZYX, CRY1 HSD17B3 3404/4885ALDH1A1 2197/4885MAOB 1186/4885
US-20110008288-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 HSD17B3 597/4885ALDH1A1 365/4885MAOB 1610/4885
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 HSD17B3 1219/4885ALDH1A1 250/4885MAOB 1687/4885
US-20110064696-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 HSD17B3 606/4885ALDH1A1 354/4885MAOB 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.